South Korea-based Bridge Biotherapeutics licensed out BB-877 to Boehringer Ingelheim for a total deal of about $1.75 billion, marking the second large transaction for fibrotic diseases that the Germany-based company inked during July 2019.
Merck agreed to acquire Tilos, a privately held biopharma company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.
Morphic Therapeutic and J&J division Janssen Biotech entered into a collaborative deal to develop novel integrin therapeutics for conditions not adequately addressed by current therapies.
Gilead Sciences Inc. is acquiring the global rights to develop and commercialize novel small molecules against two targets from South Korea-based Yuhan Corporation.
AbbVie Invests $100 Million in Morphic Therapeutic to Develop Integrin Inhibitors for Fibrotic Diseases
Weeks after Waltham, Mass.-based Morphic Therapeutic secured $80 million in Series B financing that was supported in part by AbbVie Ventures, the company struck a deal with the pharma giant to collaborate on the development of therapies for fibrosis-related indications.